Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGG-bEVs
- Development stage
- Preclinical
- Lead developer
- University of Cincinnati
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
LGG-bEVs are extracellular vesicles derived from the probiotic bacterium Lactobacillus rhamnosus GG (LGG). These bacterial extracellular vesicles (bEVs) function as therapeutic agents by delivering specific cargo, notably 5s-rRNA-derived short RNA fragments, to macrophages. In the context of myocardial ischemia/reperfusion (I/R) injury, LGG-bEVs stimulate macrophage efferocytosis—the process of clearing dead cardiomyocytes—thereby limiting sterile inflammation and cardiac remodeling. Mechanistically, the RNA cargo interacts with the coding regions of genes such as DDX5, YWHAZ, and FRMD4A, upregulating their expression to enhance phagocytic activity. Research conducted by institutions like the University of Cincinnati has demonstrated that systemic administration of LGG-bEVs in mouse models reduces inflammatory cytokine levels (IL-6, TNF-α, MCP-1) and improves long-term cardiac function post-infarction.
- Other names
- Lactobacillus rhamnosus GG-derived extracellular vesiclesprobiotic extracellular vesicles from LGG
02
Targets
DDX5 (Phosphorylated-p68 RNA helicase)FRMD4A (FERM domain-containing protein 4A)YWHA (14-3-3 protein family)
Beyond the preview
Go deeper on LGG-bEVs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGG-bEVs.